Alendronate Sodium
Product Images NDC 67296-1500

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 67296-1500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

The text shows a chart with the cumulative incidence of Hip Fractures in a Three-Year Study of FIT, comparing Placebo with Alendronate Sodium for patients with radiographic vertebral fracture at baseline. The chart displays the results in percentage format over time in months.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

Osteoporosis Treatment Studies in Postmenopausal women comparing the effect of Alendronate Sodium 10mg/day versus Placebo on Lumbar Spine BMD Percent change from Baseline over time (in months). The study was conducted in both the US and internationally, as indicated by the two labeled columns. However, the data and statistics presented in the text are insufficient and difficult to interpret due to unclear formatting and missing values.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

This is a table with information on bone mineral density (BMD) change in postmenopausal women during 2-year and 3-year studies on osteoporosis prevention. The table includes mean percent changes and standard error (SE) in BMD from baseline, as well as sodium intake information. The BMD changes are listed for the lumbar spine, femoral neck, trochanter, and total body.*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

This is a study on Paget's Disease of Bone comparing the effects of Alendronate Sodium 40 mg/day with Placebo or Etidronate 400 mg/day on the serum alkaline phosphatase. The study involved 27 participants and includes graphs showing the mean % change from baseline serum alkaline phosphatase levels over time.*

FDA Label Image

Cipla-35mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 08)

FDA Label Image

Cipla-70mg-1x4s-pack-carton (1203dd0c 809a 4409 B948 B5e816b8a63a 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.